Compare DexCom, Inc. (DXCM) vs Hut 8 Corp (HUT) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

HUT's stock is trading at $90.45, down 8.01% over the past 24 hours amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, though recent earnings have shown volatility with a mix of beats and misses. Positive developments include a strategic pivot to AI infrastructure, securing $16.8 billion in contracted revenue, and strong analyst support with a 93.75% buy rating.

The outlook is a balance of high growth potential from its AI data center expansion against significant execution risks and persistent profitability challenges. The consensus price target of $138.89 implies substantial upside if the company successfully monetizes its infrastructure investments, but investors face risks from high debt levels, competitive pressures, and reliance on future project success.